ALAlexandre Bussinger Lopes

Alexandre Bussinger Lopes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandre Bussinger Lopes has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Highly active multiple sclerosis - An important, yet inaccurate concept

    by Alexandre Bussinger Lopes, Denis Bernardi Bichuetti, Nilton Amorim de Souza, Felipe Toscano Lins de Menezes, Flavia Timbó Albuquerque, Enedina Maria Lobato de Oliveira


  • Open Access

    The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort

    by Felipe Toscano Lins de Menezes, Jéssica Monique Dias Alencar, Alexandre Bussinger Lopes, Leizian de Souza Amorim, Raquel Paiva Portugal, Flávia Timbó Albuquerque, Natasha Pryanca de Araújo Bessa, Larissa Sabino Ferreira Vicente, Nilton Amorim de Souza, Denis Bernardi Bichuetti, et al.

    Updating multiple sclerosis (MS) diagnostic criteria over recent decades may have impacted disability progression.To assess the effects of the passage of time and changes in diagnostic criteria on disability.A retrospective study of Brazilian people with relapsing-remitting MS from 1994 to 2019. Descriptive analysis compared three periods based on admission: Epoch 1 (1994–2001), 2 (2002–2010), and 3 (2011–2019). Cox regressions were performed for the outcomes of the expanded disability status scale (EDSS) 6.0 and conversion to secondary progressive MS (SPMS). We compared the three Epochs in sequence, the Poser with all McDonald criteria combined, and Poser versus each McDonald criteria (2001, 2005, 2010, and 2017). A multivariate logistic regression assessed the impact of diagnostic criteria on patients reaching EDSS 6.0.Time to diagnosis and treatment decreased across Epochs. For reaching EDSS 6.0, the Cox regression indicated a hazard ratio (HR) 63% lower for Epoch 3 compared with 1, an HR 50% lower for the McDonald criteria combined, and an HR 65% lower for McDonald 2010 compared with Poser. Regarding the conversion to SPMS, the HR was 53% lower for Epoch 3, 48% lower for the McDonald criteria combined, and 64% lower for McDonald 2010. The multivariate logistic regression demonstrated that incomplete recovery of initial symptoms was the main prognostic factor for reaching EDSS 6.0. However, transitioning diagnostic criteria from Poser to McDonald 2001 and 2005 decreased these odds by 54%.Newer diagnostic criteria have reduced the likelihood of reaching EDSS 6.0 and converting to SPMS over the past 25 years.


  • Typical demyelinating syndromes in atypical patients: case report of two intriguing cases

    by Alexandre Bussinger Lopes, Natalia Silva Fernandes, Rafael Mazzini Baptista, Janaina Reis Menezes, Bruno de Mattos Lombardi Badia, Augusto Bragança Reis Rosa

  • Open Access

    Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy

    by Fabiano Ferreira Abrantes, Marianna Pinheiro Moraes de Moraes, José Marcos Vieira de Albuquerque Filho, Jéssica Monique Dias Alencar, Alexandre Bussinger Lopes, Wladimir Bocca Vieira de Rezende Pinto, Paulo Victor Sgobbi de Souza, Enedina Maria Lobato de Oliveira, Acary de Souza Bulle de Oliveira, José Luiz Pedroso, et al.

    For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.